The stock's rise snapped a four-day losing streak.

About the Linvoseltamab Clinical Development Program Linvoseltamab is an investigational BCMAxCD3 bispecific antibody designed to bridge B-cell maturation antigen (BCMA) on MM cells with ...

The Greenburgh Black History Museum Initiative is officially live and will be exhibited at the Greenburgh Public Library, 300 Tarrytown Road, Elmsford, NY, from February 2nd through March 15th, 2025.

On April 10, 2024, the U.S. Department of Justice announced it had filed a complaint against Regeneron under the False Claims Act. According to the DOJ, the Company failed to report millions of ...

Regeneron reported Q4 2024 earnings today and declared its first-ever dividend of $0.88 per quarter. Click here to know what ...

Regeneron Pharmaceuticals beat fourth-quarter sales and profit estimates on Tuesday, on continuing demand for its eczema ...

On a per-share basis, the Tarrytown, New York-based company said it had profit of $8.06. Earnings, adjusted for stock option expense and non-recurring costs, were $12.07 per share. The results beat ...

Fourth quarter 2024 revenues increased 10% to $3.79 billion versus fourth quarter 2023Full year 2024 revenues increased 8% to $14.20 billion versus 2023; excluding RonapreveTM(a)(b), revenues increase ...

Through the generous support of Regeneron, four times a year River Journal publishes the on-site report of a high school science student from the River Towns who is paired with a Regeneron […] ...

On April 10, 2024, the U.S. Department of Justice announced it had filed a complaint against Regeneron under the False Claims Act. According to the DOJ, the Company failed to report millions of ...

Biotech giant Regeneron Pharmaceuticals, Inc. REGN is slated to report fourth-quarter and full-year 2024 results on Feb. 4, 2025. The Zacks Consensus Estimate for fourth-quarter revenues is pegged ...